Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2021)
Collaborators: Sanofi Global, Cold Agglutinin Disease Foundation (CADF)
Authors: Schmitt LA, McGee Watson PA, Pain E, Testa D
Cold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients with autoimmune hemolytic anemia. Few studies have assessed CAD symptoms, and its impact on daily life, but they did not address the patients’ perspective. To get real-world evidence of the impact that CAD has on the patient’s daily life, Carenity conducted an Internet-based survey in September 2020 among patients registered on the CAD Unraveled website and members from the Cold Agglutinin Disease Foundation.
Objective: To assess the impact of Cold Agglutinin Disease (CAD) and its related effects on patients’ daily life.